493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

2008 ◽  
Vol 134 (4) ◽  
pp. A-67 ◽  
Author(s):  
Christien J. van der Woude ◽  
Pieter C. Stokkers ◽  
Ad A. van Bodegraven ◽  
Gert A. Van Assche ◽  
Zbigniew Hebzda ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Phase I ◽  
Dose Escalation ◽  
Safety Profile ◽  
Dose Escalation Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Gut ◽  
2012 ◽  
Vol 61 (12) ◽  
pp. 1693-1700 ◽  
Author(s):  
Wolfgang Hueber ◽  
Bruce E Sands ◽  
Steve Lewitzky ◽  
Marc Vandemeulebroecke ◽  
Walter Reinisch ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohnʼs disease†

2010 ◽  
Vol 16 (10) ◽  
pp. 1708-1716 ◽  
Author(s):  
Janneke C. van der Woude ◽  
Pieter Stokkers ◽  
Ad A. van Bodegraven ◽  
Gert Van Assche ◽  
Zbigniew Hebzda ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Dose Escalation ◽  
Dose Escalation Study ◽  
Double Blind
Sign in / Sign up

Export Citation Format

Share Document